Effect of evolocumab in patients with chronic limb threatening ischemia (Evol-CLI study)
- 28 November 2024
- journal article
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 76, 91-97
Abstract
No abstract availableKeywords
Funding Information
- Amgen Inc
This publication has 16 references indexed in Scilit:
- The addition of evolocumab to maximal tolerated statin therapy improves walking performance in patients with peripheral arterial disease and intermittent claudication (Evol-PAD study)Cardiovascular Revascularization Medicine, 2023
- Association between statin therapy and amputation-free survival in patients with critical limb ischemia in the CRITISCH registryJournal of Vascular Surgery, 2017
- Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late studyInternational Journal of Cardiology, 2017
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Association Between Statin Medications and Mortality, Major Adverse Cardiovascular Event, and Amputation-Free Survival in Patients With Critical Limb IschemiaJACC, 2014
- The toe-brachial index in the diagnosis of peripheral arterial diseaseJournal of Vascular Surgery, 2013
- The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial diseaseJournal of Vascular Surgery, 2007
- Statin therapy improves cardiovascular outcome of patients with peripheral artery diseaseEuropean Heart Journal, 2004
- Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular diseaseThe American Journal of Medicine, 2003
- Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: A report from the regression growth evaluation statin studyThe American Journal of Cardiology, 1995